ASCO-GI 2023: Zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin-18.2+ (CLDN18.2+) / HER2− locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results ...
Zolbetuximab With mFOLFOX6 Meets Primary Endpoint in SPOTLIGHT Trial
ASCO-GI 2023: Zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin-18.2+ (CLDN18.2+) / HER2− locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results ...
Astellas to Present Positive Findings from Phase 3 SPOTLIGHT Trial of Zolbetuximab during 2023 ASCO GI Cancers
ASCO-GI 2023: Zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin-18.2+ (CLDN18.2+) / HER2− locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results ...
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma - Annals of Oncology
Zolbetuximab plus mFOLFOX6 successful in CLDN18.2-positive subgroup of gastric cancer - Medical Conferences
Zolbetuximab Plus mFOLFOX6 for Gastric/GEJ Cancer
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind ...
ASCO-GI 2023: Zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin-18.2+ (CLDN18.2+) / HER2− locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results ...
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma - ScienceDirect
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma - ScienceDirect
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 ...
Arturo Loaiza-Bonilla, MD MSEd on Twitter: "Very excited to participate as PI in this novel study bringing #innovative #pancreaticcancer #clinicaltrials to our patients at @CancerCenter !! #cancerresearch #precisionmedicine #targetedtherapy #biomarkers ...
Pamela Kunz, MD on Twitter: "#GI23 📢Oral Abstract Session A starting now CLAUDIN 18.2 getting lots of air time today. 🔦SPOTLIGHT Trial: Zolbetuximab + mFOLFOX vs. PBO + mFOLFOX in pts with
Gastric Cancer - Zolbetuximab Prolongs Survival - TRIAL-IN Pharma
Zolbetuximab for CLDN18.2+ GEC - Slideset Download - ASCO GI 2023 | CCO
Zolbetuximab Meets Primary Endpoint in Phase 3 SPOTLIGHT Trial in Treatment in Gastric Cancers - Onco'Zine
Zolbetuximab benefits subset of patients with gastric, gastroesophageal junction cancer
Asco-GI 2023 – zolbetuximab sheds light on Claudin18.2 expression | Evaluate
Asco-GI 2023 – zolbetuximab sheds light on Claudin18.2 expression | Evaluate
Results from Astellas' Phase 3 SPOTLIGHT Trial of Investigational Zolbetuximab Published in The Lancet
SPOTLIGHT: zolbetuximab plus chemotherapy prolongs PFS and OS in CLDN18.2+ metastatic gastric cancer | VJOncology
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 ...
